UCB SA (OTCMKTS:UCBJF – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $195.88 and last traded at $195.88, with a volume of 87 shares. The stock had previously closed at $174.00.
UCB Price Performance
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average price is $179.62 and its 200-day moving average price is $164.54.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Business Services Stocks Investing
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Using the MarketBeat Dividend Yield Calculator
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- What does consumer price index measure?
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
